A study on efficacy of HB35FA against UV-induced skin inflammation.
Not Applicable
- Conditions
- Healthy adults
- Registration Number
- JPRN-UMIN000028964
- Lead Sponsor
- Kao Corporation
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- Male
- Target Recruitment
- 25
Inclusion Criteria
Not provided
Exclusion Criteria
-Subjects with photosensitive dermatitis. -Subjects with clinically-significant disorder at the test site -Subjects who go to hospital regularly or routinely taking oral medicine for disease: gastrointestinal system, liver, kidney, heart, and blood pressure. -Subjects who are routinely taking oral medicine for sunburn, chloasma, and freckles. -Subjects who are deemed inappropriate to participate in this study by the principle investigator.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method -Evaluation of anti-inflammatory effect after 3 weeks of HB35FA administration.
- Secondary Outcome Measures
Name Time Method -Change of inflammatory markers in the stratum corneum after 3 weeks of HB35FA administration. -Change of fecal microbiome and metabolome after 4 weeks of HB35FA administration. -Change of blood inflammatory markers after 4 weeks of HB35FA administration.